We report a case of fl uconazole-resistant oropharyngeal colonization caused by a strain of Candida glabrata that rapidly regained susceptibility once prophylaxis with this agent was discontinued and echinocandin therapy was initiated. Isolates collected before and after discontinuation of fl uconazole were confi rmed to be isogenic by RAPD analysis. Transcription analysis demonstrated constitutive expression of genes encoding effl ux pumps in the isolate recovered on fl uconazole prophylaxis and transient expression in those isolates collected after fl uconazole was discontinued.
Introduction
Fluconazole prophylaxis is used routinely for prophylaxis during hemopoietic stem cell transplantation (HSCT). Emergence of fl uconazole-resistant Candida glabrata is increasing, necessitating the use of alternative antifungal therapy [ 1, 2 ] . The development of resistance generally occurs following chronic exposure to an antifungal agent. Here, we report the rapid loss of fl uconazole resistance in isogenic C. glabrata isolates from a HSCT patient following discontinuation of this azole followed by short-term echinocandin use.
A 58-year-old male diagnosed with stage III IgG Kappa multiple myeloma was referred to the South Texas Veterans to Micafungin, dosed 100 mg daily for a 9 day course of prophylaxis. Ten days after transplantation, engraftment was reached and antifungal prophylaxis was discontinued. Interestingly, C. glabrata isolates 8140 and 8152 collected 6 and 14 days, respectively, after transplantation and after discontinuation of fl uconazole were found to be fl uconazole susceptible (MICs of 2 and 8 μg/ml, respectively) using CLSI M27-A3 methodology.
Materials and methods
To determine if these C. glabrata strains were isogenic, random amplifi cation of polymorphic DNA (RAPD) analysis using previously described primers (OPA-18, OPE-18, and AP50-1) was utilized ( Table 1 ) [ 6, 7 ] . RAPD profi les were compared following PCR amplifi cation with each other and C. glabrata ATCC 2001, an unrelated reference strain, using genomic DNA extracted from using the Masterpure Yeast DNA Purifi cation Kit (Epicentre Biotechnologies, Madison, WI). Band patterns were visualized on 1.2% w/v agarose gels illuminated with UV light following ethidium bromide staining. As shown in Fig. 1 , the band patterns were identical for 8127, 8140, and 8152 with each of the three primers used, and distinct from those of ATCC 2001, confi rming the isogenicity of the isolates collected from the patient.
To test for upregulation of genes associated with resistance in C. glabrata , relative gene expression was measured in triplicate before and after in vitro exposure to fl uconazole. Strains were adjusted to a starting inoculum of ~1ϫ10 4 cells/ml and incubated at 37°C in YPD with shaking to ~1ϫ10 6 cells/ml, after which they were exposed to control (sterile water) or fl uconazole 64 μg/ml at 37°C for an additional 12 h. Cells were harvested by centrifugation and total RNA extracted using the Yeastar RNA Kit Primer Sequence 
Results and discussion
For isolate 8127 recovered during fl uconazole prophylaxis, the transcription levels of CDR1 , PDH1 , and PDR1 were elevated without in vitro exposure to this azole (у2.25-fold compared to ATCC 2001; Fig. 2 A) . However, the expression of these genes was not further increased upon exposure to fl uconazole. These results suggest constitutive expression of these genes affecting fl uconazole susceptibility within this isolate. In contrast, in vitro exposure to fl uconazole increased the expression of these genes in the isolates recovered from the patient's oral wash following the discontinuation of azole prophylaxis ( Fig. 2 B & C) . Transcription levels of CDR1 , PDR1 , and PDH1 were signifi cantly increased in isolate 8152 (7.0 Ϯ 2.7, 3.6 Ϯ 0.05, and 2.7 Ϯ 0.4 fold, respectively; P Ͻ0.05) following exposure to fl uconazole. In isolate 8140, CDR1 transcription also increased 4.0 Ϯ 0.8 fold following exposure to fl uconazole, although this did not reach statistical signifi cance. These data suggest a transient and reversible increase in the expression of these genes affecting fl uconazole activity in the isolates recovered after the discontinuation of fl uconazole.
To our knowledge, this is the fi rst case report describing rapid loss of fl uconazole resistance following discontinuation of this agent. After detection of the C. glabrata isolate resistant to fl uconazole, a clinical decision was made to change antifungal prophylaxis to an echinocandin. Although it is unknown if this switch in prophylaxis regimens resulted in the rapid loss of fl uconazole resistance, the rapid decrease in MICs to this azole after only 6 days is impressive. This loss of resistance is in contrast to previous reports in which resistance develops over time and has been attributed to gain of function mutations within the transcription factor PDR1 [ 9 ] . Whether this occurred in our patient cannot be determined as isolates prior to fl uconazole prophylaxis azole are not available. It is unknown if this loss of resistance is clinically signifi cant as the patient was colonized but without oropharyngeal candidiasis. Furthermore, it is unknown if fl uconazole could be used for subsequent therapy in this patient. However, this may be problematic as in vitro exposure to fl uconazole rapidly increased resistant gene expression in these susceptible isolates. Any future use of fl uconazole in such a patient should include antifungal susceptibility monitoring. Confl ict of interest: SDW, ACV, SK, SB, SAL, WRK, JJT, COF: None to declare.N.P.W. has received research support from Pfi zer, Schering-Plough, and CyDex Pharmaceuticals. T.F.P. has received research support from Merck, Pfi zer, Schering-Plough, and Nektar Therapeutics, has served on the speakers bureau for Merck and Pfi zer, and as a consultant for Basilea, Merck, Nektar, Pfi zer, and Toyama. S.W.R. has received research support from Pfi zer, Schering-Plough, and Astellas.
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